Adult Clinical Trials

New Anti-Cancer Drugs (Phase I)

If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact the Phase I Clinical Trials Office at 919.684.6342.

16 trials identified.

Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects with Advanced Malignancies
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Herbert Hurwitz
Contact: Denise Morin, RN
Phone: 919.684.6342
Reference Number: 00005540
View this trial at ClinicalTrials.gov

A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Michael Morse
Contact: Leslie Lewis, RN
Phone: 919.684.6342
Reference Number: 00048169
View this trial at ClinicalTrials.gov

A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABT-165, a Dual Variable Domain Immunoglobulin in Subjects with Advanced Solid Tumors
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: John Strickler
Contact: Leslie Lewis, RN
Phone: 919.684.6342
Reference Number: 00049036
View this trial at ClinicalTrials.gov

A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: John Strickler
Contact: Phase I Clinical Trials Office
Phone: 919.684.6342
Reference Number: 00052355

First-in-Human Dose-Escalation Study of TEW-7197 Monotherapy in Subjects with Advanced Stage Solid Tumors
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Jeffrey Clarke
Contact: Phase 1 Oncology Clinical Trials Office
Phone: 919.684.6342
Reference Number: 00053834
View this trial at ClinicalTrials.gov

A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Niharika Mettu
Contact: Phase I Oncology Clinical Research Team
Phone: 919.684.6342
Reference Number: 00058492
View this trial at ClinicalTrials.gov

A Phase I/IIa Study of BMS 986148, a Mesothelin Directed Antibody Drug Conjugate, in Subjects with Select Advanced Solid Tumors
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Jeffrey Clarke
Contact: Phase I Oncology Clinical Research Team
Phone: 919.684.6342
Reference Number: 00061125
View this trial at ClinicalTrials.gov

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Niharika Mettu
Contact: Phase I Oncology Clinical Research Team
Phone: 919.684.6342
Reference Number: 00061567
View this trial at ClinicalTrials.gov

A Phase I/II, open label, multicenter study of the safety and efficacy of LAG525 single agent and in combination with PDR001 administered to patients with advanced malignancies
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Tian Zhang
Contact: Phase 1 Oncology Clinical Trials Office
Phone: 919.684.6342
Reference Number: 00062919
View this trial at ClinicalTrials.gov

A FIRST-IN-HUMAN STUDY OF REPEAT DOSING WITH REGN2810, A MONOCLONAL, FULLY HUMAN ANTIBODY TO PROGRAMMED DEATH 1 (PD-1), AS SINGLE THERAPY AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES, IN PATIENTS WITH ADVANCED MALIGNANCIES
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Tian Zhang
Contact: Phase 1 Oncology Clinical Trials Office
Phone: 919.684.6342
Reference Number: 00063093
View this trial at ClinicalTrials.gov

A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Malignancies
Phase: N/A
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Jeffrey Clarke
Contact: Phase 1 Oncology Clinical Trials Office
Phone: 919.684.6342
Reference Number: 00068071
View this trial at ClinicalTrials.gov

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Niharika Mettu
Contact: Phase 1 Oncology Clinical Trials Office
Phone: 919.684.6342
Reference Number: 00068096
View this trial at ClinicalTrials.gov

An Open-Label, Multicenter, Dose Escalation and Expansion Phase Ib Study to Evaluate the safety, pharmacokinetcs, and therapeutic activity of RO6958688 In Combination with Atezolizumab in Patients with Locally Advanced and/or Metastatic CEA-Positive Solid Tumors
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: John Strickler
Contact: Phase 1 Oncology Clinical Trials Office
Phone: 919.684.6342
Reference Number: 00068531
View this trial at ClinicalTrials.gov

My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib, and Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Jeffrey Clarke
Contact: Phase 1 Oncology Clinical Trials Office
Phone: 919.684.6342
Reference Number: 00070333
View this trial at ClinicalTrials.gov

A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: John Strickler
Contact: Phase 1 Oncology Clinical Trials Office
Phone: 919.684.6342
Reference Number: 00070425
View this trial at ClinicalTrials.gov

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Niharika Mettu
Contact: Phase 1 Oncology Clinical Trials Office
Phone: 919.684.6342
Reference Number: 00073140
View this trial at ClinicalTrials.gov